Biomaterials forum "blueprint" to be developed by FDA/NIH/industry/academic committee.
This article was originally published in The Gray Sheet
Executive Summary
BIOMATERIALS FORUM "BLUEPRINT" TO BE DEVELOPED by a four-person planning committee appointed at a March 28 meeting of FDA's Science Board. The committee, to be chaired by Bernie Liebler, director, technology and regulatory affairs, Health Industry Manufacturers Association, will develop a plan for the HIMA-proposed forum, which will likely consist of one or more gatherings of representatives from industry, academia, FDA and other governmental agencies who will consider FDA's handling of new biomaterials in medical products.